Guducuoglu, HuseyinBozkurt, HamzaYaman, GorkemKutluay, NihatBerktas, Mustafa2025-05-102025-05-1020051307-94412147-2939https://hdl.handle.net/20.500.14720/4586In this study, patients infected with HBV with uncharacteristic serologic markers were interpreted and their probable clinical stages were determined. With this purpose, 75 patients were evaluated for HBV-DNA and hepatitis serologic markers. HBV-DNA results were obtained using bDNA-Bayer kits and serologic markers were detected using microparticle enzyme immunoassay (MEIA) kits. From 75 patients, 54 (72%) were HBV-DNA positive, and 35 (64.8%) of them were HBeAg positive. From 21 (28%) patients who are HBV-DNA negative, only 1 (4.8%) patient was HBeAg positive. HBsAg, HBeAg, anti-HBe, anti-HBc IgM and anti-HBc IgG of 46 patients were compared with HBV-DNA results simultaneously and 31 (67.4%) patients were HBV-DNA positive and HBsAg, HBeAg, anti-HBe, anti-HBc IgM, anti-HBc IgG results were positive in 29 (63%), 22 (48%), 7 (15%), 1 (2%), and 29 (63%) patients respectively. In 15 (33%) patients with negative HBV-DNA results, HBsAg in 14 (30%), HBeAg in 1 (2%), anti-HBe in 13 (28%), anti-HBc IgG in 14 (30%) were positive, and none of them were positive for anti-HBc IgM.trinfo:eu-repo/semantics/closedAccessHbv-DnaSerologic MarkersArticle103N/AN/A158163WOS:000217138900006